KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares OutstandingShares RepurchasedShort-Term Debt issuances
Ratios

Idexx Laboratories (IDXX) EBIAT (2016 - 2026)

Idexx Laboratories has reported EBIAT over the past 17 years, most recently at $248.2 million for Q4 2025.

  • For Q4 2025, EBIAT rose 14.82% year-over-year to $248.2 million; the TTM value through Dec 2025 reached $1.1 billion, up 19.33%, while the annual FY2025 figure was $1.1 billion, 19.33% up from the prior year.
  • EBIAT for Q4 2025 was $248.2 million at Idexx Laboratories, down from $274.6 million in the prior quarter.
  • Over five years, EBIAT peaked at $294.0 million in Q2 2025 and troughed at $132.0 million in Q2 2022.
  • A 5-year average of $210.8 million and a median of $208.3 million in 2021 define the central range for EBIAT.
  • Biggest five-year swings in EBIAT: skyrocketed 82.64% in 2021 and later tumbled 34.86% in 2022.
  • Year by year, EBIAT stood at $162.8 million in 2021, then grew by 5.8% to $172.2 million in 2022, then increased by 12.96% to $194.5 million in 2023, then grew by 11.12% to $216.1 million in 2024, then increased by 14.82% to $248.2 million in 2025.
  • Business Quant data shows EBIAT for IDXX at $248.2 million in Q4 2025, $274.6 million in Q3 2025, and $294.0 million in Q2 2025.